Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07276581 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

Study acronym: LaunchPAD-RA
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 144 → 147 locations Eligibility criteria expanded, about 9 words · Study description revised Show 2 more changesShow less
    • Eligibility criteria expanded, about 9 words
    • Study description revised
  2. Site details revised at 27 of 144 sitesv6
  3. Trial sites expanded: 139 → 144 locations Study description revisedv5 Show 1 more changeShow less
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 124 to 139v4
  5. Study sites: 101 to 124v3
  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 27 to 101v2 Show 1 more changeShow less
    • Study sites: 27 to 101
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Trial Details
NCT Number NCT07276581
Lead Sponsor AstraZeneca
Conditions Rheumatoid Arthritis
Enrollment 320 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov